Concomitant driver mutations included activating mutations in classic oncogenes (e.g., KRAS, NRAS, EGFR, and PIK3CA), as well as loss-of-function mutations in tumor suppressors (e.g., BRCA1/2 and PTEN). This evidence concerns the gene KRAS and neoplasm.